{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:30:49Z","timestamp":1783632649701,"version":"3.55.0"},"reference-count":23,"publisher":"Archives of Endocrinology and Metabolism","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,21]]},"DOI":"10.20945\/2359-3997000000659","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T13:06:52Z","timestamp":1687784812000},"source":"Crossref","is-referenced-by-count":4,"title":["Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAFV600E mutations: a case report"],"prefix":"10.20945","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-6798","authenticated-orcid":false,"given":"Yan-Jun","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2471-8255","authenticated-orcid":false,"given":"Shao-Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7004-0954","authenticated-orcid":false,"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-8253","authenticated-orcid":false,"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-2161","authenticated-orcid":false,"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-0617","authenticated-orcid":false,"given":"Xiang-Xiang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0731-1445","authenticated-orcid":false,"given":"Zhu-Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-2731","authenticated-orcid":false,"given":"Hai-Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-4378","authenticated-orcid":false,"given":"Xing-Wei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-4246","authenticated-orcid":false,"given":"Ruo-Chuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20230626090644_B1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1089\/thy.2016.0100","article-title":"Systematic Review of Trends in the Incidence Rates of Thyroid Cancer","volume":"26","author":"Wiltshire","year":"2016","unstructured":"1 Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic Review of Trends in the Incidence Rates of Thyroid Cancer. Thyroid. 2016;26:1541-52.","journal-title":"Thyroid"},{"key":"key20230626090644_B2","article-title":"Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013","volume":"11","author":"Olson","year":"2019","unstructured":"2 Olson E, Wintheiser G, Wolfe KM, Droessler J, Silberstein PT. Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013. Cureus. 2019;11:e4127.","journal-title":"Cureus"},{"key":"key20230626090644_B3","first-page":"27","article-title":"Surgical treatment of locally advanced thyroid cancer","volume":"5","author":"Roka","year":"2020","unstructured":"3 Roka R. Surgical treatment of locally advanced thyroid cancer. Innov Surg Sci. 2020;5:27-34.","journal-title":"Innov Surg Sci"},{"key":"key20230626090644_B4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0960-7404(03)00032-X","article-title":"Locally advanced differentiated thyroid cancer","volume":"12","author":"Kebebew","year":"2003","unstructured":"4 Kebebew E, Clark OH. Locally advanced differentiated thyroid cancer. Surg Oncol. 2003;12:91-9.","journal-title":"Surg Oncol"},{"key":"key20230626090644_B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijscr.2017.10.010","article-title":"Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report","volume":"41","author":"Tsuboi","year":"2017","unstructured":"5 Tsuboi M, Takizawa H, Aoyama M, Tangoku A. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report. Int J Surg Case Rep. 2017;41:89-92.","journal-title":"Int J Surg Case Rep"},{"key":"key20230626090644_B6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000494880","article-title":"Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report","volume":"8","author":"Stewart","year":"2019","unstructured":"6 Stewart KE, Strachan MWJ, Srinivasan D, MacNeill M, Wall L, Nixon IJ. Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report. Eur Thyroid J. 2019;8:102-7.","journal-title":"Eur Thyroid J"},{"key":"key20230626090644_B7","first-page":"370","article-title":"Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer","volume":"62","author":"Danilovic","year":"2018","unstructured":"7 Danilovic DLS, Castro G Jr, Roitberg FSR, Vanderlei FAB, Bonani FA, Freitas RMC, et al. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch Endocrinol Metab. 2018;62:370-5.","journal-title":"Arch Endocrinol Metab"},{"key":"key20230626090644_B8","article-title":"Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report","volume":"100","author":"Zhang","year":"2021","unstructured":"8 Zhang Y, Deng X, Ding Z, Kang J, Wu B, Guo B, et al. Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report. Medicine (Baltimore). 2021;100:e25191.","journal-title":"Medicine (Baltimore)"},{"key":"key20230626090644_B9","doi-asserted-by":"crossref","first-page":"626076","DOI":"10.3389\/fonc.2021.626076","article-title":"Case Report: Anlotinib Therapy in a Patient with Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations","volume":"11","author":"Su","year":"2021","unstructured":"9 Su Y, Cheng S, Qian J, Zhang M, Li T, Zhang Y, et al. Case Report: Anlotinib Therapy in a Patient with Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations. Front Oncol. 2021;11:626076.","journal-title":"Front Oncol"},{"key":"key20230626090644_B10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00104-020-01262-z","article-title":"Resektionsstrategien beim lokal fortgeschrittenen Schilddr\u00fcsenkarzinom [Resection strategy for locally advanced thyroid carcinoma]","volume":"91","author":"Musholt","year":"2020","unstructured":"10 Musholt TJ. Resektionsstrategien beim lokal fortgeschrittenen Schilddr\u00fcsenkarzinom [Resection strategy for locally advanced thyroid carcinoma]. Chirurg. 2020;91:1030-7.","journal-title":"Chirurg"},{"key":"key20230626090644_B11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.21037\/atm-18-1301","article-title":"Prognostic factors and the effect of radioiodine on patients with locally advanced differentiated thyroid cancer","volume":"8","author":"Yao","year":"2020","unstructured":"11 Yao Y, Cheng S, Xu X, Chen X, Chen W, Qian Y, et al. Prognostic factors and the effect of radioiodine on patients with locally advanced differentiated thyroid cancer. Ann Transl Med. 2020;8:928.","journal-title":"Ann Transl Med"},{"key":"key20230626090644_B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","unstructured":"12 Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.","journal-title":"Thyroid"},{"key":"key20230626090644_B13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1186\/s12885-019-6369-7","article-title":"A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine","volume":"19","author":"Fleeman","year":"2019","unstructured":"13 Fleeman N, Houten R, Chaplin M, Beale S, Boland A, Dundar Y, et al. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer. 2019;19:1209.","journal-title":"BMC Cancer"},{"key":"key20230626090644_B14","first-page":"6438352","article-title":"A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy","volume":"2020","author":"Iwasaki","year":"2020","unstructured":"14 Iwasaki H, Toda S, Ito H, Nemoto D, Murayama D, Okubo Y, et al. A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy. Case Rep Endocrinol. 2020;2020:6438352.","journal-title":"Case Rep Endocrinol"},{"key":"key20230626090644_B15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3389\/fendo.2019.00712","article-title":"Neoadjuvant Multikinase Inhibitor in Patients with Locally Advanced Unresectable Thyroid Carcinoma","volume":"10","author":"Nava","year":"2019","unstructured":"15 Nava CF, Scheffel RS, Cristo AP, Ferreira CV, Weber S, Zanella AB, et al. Neoadjuvant Multikinase Inhibitor in Patients with Locally Advanced Unresectable Thyroid Carcinoma. Front Endocrinol (Lausanne). 2019;10:712.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20230626090644_B16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: First Global Approval","volume":"78","author":"Syed","year":"2018","unstructured":"16 Syed YY. Anlotinib: First Global Approval. Drugs. 2018;78:1057-62.","journal-title":"Drugs"},{"key":"key20230626090644_B17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","unstructured":"17 Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene. 2018;654:77-86.","journal-title":"Gene"},{"key":"key20230626090644_B18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","unstructured":"18 Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9:105.","journal-title":"J Hematol Oncol"},{"key":"key20230626090644_B19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2174\/1871520620666200718235748","article-title":"Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1\/2 Pathway in H446 Cells","volume":"21","author":"Tang","year":"2021","unstructured":"19 Tang X, Zheng Y, Jiao D, Chen J, Liu X, Xiong S, et al. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1\/2 Pathway in H446 Cells. Anticancer Agents Med Chem. 2021;21:747-55.","journal-title":"Anticancer Agents Med Chem"},{"key":"key20230626090644_B20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.20892\/j.issn.2095-3941.2020.0024","article-title":"Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling","volume":"17","author":"Qin","year":"2020","unstructured":"20 Qin T, Liu Z, Wang J, Xia J, Liu S, Jia Y, et al. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol Med. 2020;17:753-67.","journal-title":"Cancer Biol Med"},{"key":"key20230626090644_B21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","unstructured":"21 Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.","journal-title":"J Hematol Oncol"},{"key":"key20230626090644_B22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/ERC-17-0558","article-title":"Antitumor effects of anlotinib in thyroid cancer","volume":"26","author":"Ruan","year":"2019","unstructured":"22 Ruan X, Shi X, Dong Q, Yu Y, Hou X, Song X, et al. Antitumor effects of anlotinib in thyroid cancer. Endocr Relat Cancer. 2019;26:153-64.","journal-title":"Endocr Relat Cancer"},{"key":"key20230626090644_B23","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.1073\/pnas.2004707117","article-title":"TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel","volume":"117","author":"Tan","year":"2020","unstructured":"23 Tan J, Liu R, Zhu G, Umbricht CB, Xing M. TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proc Natl Acad Sci U S A. 2020;117:15846-51.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T13:07:17Z","timestamp":1687784837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/neoadjuvant-therapy-with-anlotinib-in-a-locally-advanced-and-pulmonary-metastasis-ptc-patient-harboring-tert-promoter-and-brafv600e-mutations-a-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,21]]}},"alternative-id":["10.20945\/2359-3997000000659"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000659","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e000659"}}